Pazopanib gets green light from NICE but use of bevacizumab rejected

摘要

Pazopanib (Votrient; GlaxoSmithKline) has been approved as first-line treatment for people with advanced renal cell carcinoma in the latest round of National Institute for Health and Clinical Excellence appraisals. In separate guidance, bevacizumab (Avastin; Roche), in combination with a taxane for the first-line treatment of metastatic breast cancer, was not approved for use within the NHS in England and Wales.Pazopanib will offer patients an additional option to sunitinib and can be prescribed for patients who have not received prior cytokine therapy and who have Eastern Cooperative Oncology Group performance status of 0 or 1, NICE says.